Volume 140, Issue 2, Pages e1 (February 2011)

Slides:



Advertisements
Similar presentations
Volume 50, Issue 4, Pages (April 2009)
Advertisements

Volume 65, Issue 1, Pages S2-S21 (October 2016)
Volume 146, Issue 2, Pages (February 2014)
Pathogenesis and Treatment of Hepatitis E Virus Infection
Volume 138, Issue 4, Pages e7 (April 2010)
Volume 138, Issue 5, Pages e10 (May 2010)
Coinfection With HIV-1 and HCV—A One-Two Punch
Volume 143, Issue 4, Pages e4 (October 2012)
Volume 140, Issue 2, Pages e2 (February 2011)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 132, Issue 2, Pages (February 2007)
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
Volume 140, Issue 2, Pages e1 (February 2011)
Volume 140, Issue 7, Pages (June 2011)
Volume 154, Issue 4, Pages e6 (March 2018)
Volume 141, Issue 4, Pages e6 (October 2011)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 141, Issue 3, Pages e4 (September 2011)
Volume 134, Issue 5, Pages e1 (May 2008)
Pathogenesis and Treatment of Hepatitis E Virus Infection
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non–genotype 1 infection by Julian Schulze zur Wiesch,
Volume 132, Issue 2, Pages (February 2007)
Volume 140, Issue 3, Pages e3 (March 2011)
Volume 143, Issue 4, Pages e9 (October 2012)
Volume 134, Issue 5, Pages (May 2008)
Volume 128, Issue 2, Pages (February 2005)
Volume 133, Issue 4, Pages (October 2007)
Volume 133, Issue 3, Pages (September 2007)
Volume 134, Issue 5, Pages (May 2008)
Covering the Cover Gastroenterology
Volume 138, Issue 4, Pages (April 2010)
Volume 143, Issue 6, Pages e4 (December 2012)
Volume 154, Issue 4, Pages (March 2018)
Volume 155, Issue 5, Pages e2 (November 2018)
Volume 134, Issue 7, Pages e2 (June 2008)
Volume 136, Issue 7, Pages (June 2009)
Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy  Steven G. Deeks, Bruce D. Walker 
Volume 132, Issue 2, Pages (February 2007)
Volume 134, Issue 7, Pages e3 (June 2008)
Volume 138, Issue 2, Pages e4 (February 2010)
Volume 65, Issue 6, Pages (December 2016)
Volume 144, Issue 2, Pages (February 2013)
Volume 124, Issue 7, Pages (June 2003)
Impact of New Hepatitis C Treatments in Different Regions of the World
Christoph Sarrazin, Stefan Zeuzem  Gastroenterology 
Volume 142, Issue 6, Pages (May 2012)
Laura Rotundo, Sushil Ahlawat  Gastroenterology 
Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins  Harel Dahari, Stephen M. Feinstone,
Volume 127, Issue 3, Pages (September 2004)
Volume 134, Issue 7, Pages e2 (June 2008)
Effect of Human Immunodeficiency Virus and Antiretrovirals on Outcomes of Hepatitis C: A Systematic Review From an Epidemiologic Perspective  Jennifer.
Volume 137, Issue 5, Pages (November 2009)
Volume 138, Issue 1, Pages e2 (January 2010)
Volume 117, Issue 6, Pages (December 1999)
Volume 137, Issue 4, Pages e6 (October 2009)
Coinfection With HIV-1 and HCV—A One-Two Punch
Volume 15, Issue 6, Pages (December 2001)
A View to Natural Killer Cells in Hepatitis C
Interleukin-28b: A Key Piece of the Hepatitis C Virus Recovery Puzzle
Volume 147, Issue 4, Pages e8 (October 2014)
Volume 132, Issue 1, Pages 5-6 (January 2007)
Volume 123, Issue 4, Pages (October 2002)
Treatment failure in hepatitis C: Mechanisms of non-response
Pathogenesis and Treatment of Hepatitis E Virus Infection
ERAP1 allotypes shape the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection  Janine Kemming, Emma Reeves,
Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?  Masaru Enomoto, Yoshiki Murakami,
Kathleen E. Corey, Andrew S
Volume 115, Issue 4, Pages (October 1998)
Volume 15, Issue 6, Pages (December 2001)
Volume 24, Issue 4, Pages e3 (October 2018)
Presentation transcript:

Volume 140, Issue 2, Pages 686-696.e1 (February 2011) Spontaneous Control of HCV Is Associated With Expression of HLA-B*57 and Preservation of Targeted Epitopes  Arthur Y. Kim, Thomas Kuntzen, Joerg Timm, Brian E. Nolan, Melanie A. Baca, Laura L. Reyor, Andrew C. Berical, Andrea J. Feller, Kristin L. Johnson, Julian Schulze Zur Wiesch, Gregory K. Robbins, Raymond T. Chung, Bruce D. Walker, Mary Carrington, Todd M. Allen, Georg M. Lauer  Gastroenterology  Volume 140, Issue 2, Pages 686-696.e1 (February 2011) DOI: 10.1053/j.gastro.2010.09.042 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Association of HLA class I types with HCV outcomes. Risk ratios with 95% confidence intervals representing the effect size of the association of various HLA types and HCV chronicity or clearance. *P < .05. Gastroenterology 2011 140, 686-696.e1DOI: (10.1053/j.gastro.2010.09.042) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Association of outcomes of both HIV-1 and HCV in mono- and co-infected individuals. (A) Prevalence of HLA-B*57 in various subgroups present in this study. Spontaneous control of HCV was defined as viral titers <600 IU/mL on 2 consecutive plasma specimens at least 3 months apart in the absence of any history of anti-HCV treatment. If subjects were identified during the acute phase, HCV RNA values >1 year from the acute phase of infection were used for classification. All with HCV control includes HIV positive subjects. Spontaneous control of HIV-1 was defined as HIV-1 viral load <2000 copies/mL in the absence of antiretroviral therapy. (B) HIV-1 viral loads were measured at time of enrollment (if off therapy) or were determined from measured values before starting antiretroviral therapy (see Materials and Methods). Co-infected persons with HCV clearance exhibited lower HIV-1 viral titers compared with co-infected persons with HCV persistence. Gastroenterology 2011 140, 686-696.e1DOI: (10.1053/j.gastro.2010.09.042) Copyright © 2011 AGA Institute Terms and Conditions

Figure 3 Polymorphisms in HCV genotype 1a virus associated with HLA-B*57 and relative recognition by CD8+ T-cell responses. (A) Association of polymorphisms with HLA-B*57 carriage for 2 of the 3 epitopes tested, revealing enrichment of changes in the E2 NW9 and NS5 KF9 epitopes targeted by HLA-B*57−restricted responses. The analysis counts mutations within the epitope at any position, as described in Tim et al.3 (B) Specific variants noted in the 2 epitopes listed, stratified by HLA-B*57 status. X represents multiple variants at that site; for E2-NW9 at position 546, L to X (A, Q, R, G, or M); for NS5-KF9, changes include position 2629 K to X (Q, N, S), position 2630 S to X (A, H, R, C, T), position 2633, T to X (A, N, S, or V). For the NS5 epitope, this analysis reveals a change in position NS5-2632 (K to R) that was found more frequently in non-B57 individuals. (C−E) Peptide-titration curves showing the number of spot-forming cells (SFC) in an ELISpot containing enriched cell lines specific for (C) E2-NW9 and (D) NS5-KF9 (square) vs peptides containing variants found in HLA-B*57 individuals, while (E) shows a cell line enriched for NS5-KF9−specific cells tested against variants found in non−HLA-B*57 individuals. Gastroenterology 2011 140, 686-696.e1DOI: (10.1053/j.gastro.2010.09.042) Copyright © 2011 AGA Institute Terms and Conditions

Figure 4 HLA-B*57−restricted responses against genotype 1a virus do not recognize peptides corresponding to the infecting virus from a genotype 1b outbreak. Peptide titration curves of highly enriched cell lines specific against the (A) E2-NW9 and (B) NS5-KF9 epitope against the reference sequence, genotype 1b consensus, and the corresponding sequence from the Irish strain. Panel (C) is an intracellular cytokine staining for interferon-γ, testing the cell-line enriched for CD8 T cells recognizing NS5-KF9 against the reference sequence, the genotype 1b consensus, and the corresponding sequence from the Irish strain. Gastroenterology 2011 140, 686-696.e1DOI: (10.1053/j.gastro.2010.09.042) Copyright © 2011 AGA Institute Terms and Conditions

Figure 5 Longitudinal analysis of an acutely infected individual (AC-2) with HLA-B*57−restricted response against NS5. (A) Clinical course: after a detectable viral load, viral control was seen for several months. Virus became detectable and sequencing revealed this was the same initial strain, mutated in the regions that may be targeted by E2-NW9 and NS5-KF9 (bulk sequence indicating the majority sequence is shown in Panel B). (C) Effect of the mutations found within NS5-KF9 on T-cell recognition; the T to I mutation at position 2633 suggested partial recognition, the additional mutations at positions 2629 and 2632 that emerged at week 58 resulted in abrogation of recognition from the NS5-KF9 response. (D) Ex vivo data at a time point with a relatively large response, showing similar patterns of recognition of the autologous mutations and indicating that stimulation did not select only the most avid and/or least cross-reactive T cells in cultured cell lines. Gastroenterology 2011 140, 686-696.e1DOI: (10.1053/j.gastro.2010.09.042) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Fig. 1 Gastroenterology 2011 140, 686-696.e1DOI: (10.1053/j.gastro.2010.09.042) Copyright © 2011 AGA Institute Terms and Conditions